The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
E7208: A randomized phase II trial of irinotecan and cetuximab (IC) versus IC plus ramucirumab (ICR) in second line therapy of KRAS wild type colorectal cancer (CRC).
 
Howard S. Hochster
Consulting or Advisory Role - Bristol-Myers Squibb
 
Paul J. Catalano
No Relationships to Disclose
 
Edith P. Mitchell
Honoraria - Sanofi
Consulting or Advisory Role - Genentech
Research Funding - Genentech (Inst); sanofi (Inst)
 
Deirdre Jill Cohen
No Relationships to Disclose
 
Peter J. O'Dwyer
Expert Testimony - Lilly
 
Al Bowen Benson
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Genentech/Roche; Lilly/ImClone; Merck Serono; Merck/Schering Plough; Sanofi; Spectrum Pharmaceuticals
Research Funding - advanced accelerator applications; Amgen; Astellas Pharma; Bayer/Onyx; Genentech (I); Gilead Sciences; Novartis
Travel, Accommodations, Expenses - Bayer; Genentech/Roche; Lilly/ImClone; Sanofi; Spectrum Pharmaceuticals